Avoro Capital Advisors LLC Buys 5,808,080 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Avoro Capital Advisors LLC increased its stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 116.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 10,808,080 shares of the company’s stock after buying an additional 5,808,080 shares during the period. Centessa Pharmaceuticals accounts for about 3.4% of Avoro Capital Advisors LLC’s portfolio, making the stock its 11th largest holding. Avoro Capital Advisors LLC owned 8.07% of Centessa Pharmaceuticals worth $262,096,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. DNB Asset Management AS bought a new stake in shares of Centessa Pharmaceuticals during the third quarter worth approximately $218,000. Campbell & CO Investment Adviser LLC acquired a new position in Centessa Pharmaceuticals in the 2nd quarter valued at $218,000. GSA Capital Partners LLP bought a new position in Centessa Pharmaceuticals during the 3rd quarter worth $455,000. China Universal Asset Management Co. Ltd. increased its position in Centessa Pharmaceuticals by 4.8% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock worth $252,000 after buying an additional 870 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Centessa Pharmaceuticals during the third quarter worth $572,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Wolfe Research assumed coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $40.00 price target on the stock. Piper Sandler reiterated an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Oppenheimer increased their target price on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. Finally, Guggenheim raised their target price on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Centessa Pharmaceuticals has an average rating of “Buy” and an average target price of $39.80.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Iqbal J. Hussain sold 38,951 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the transaction, the insider directly owned 57,645 shares of the company’s stock, valued at $1,449,771.75. The trade was a 40.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Karen M. Anderson sold 120,029 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.25, for a total value of $3,150,761.25. Following the sale, the insider owned 62,085 shares in the company, valued at approximately $1,629,731.25. The trade was a 65.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 233,186 shares of company stock valued at $6,082,890. 7.09% of the stock is currently owned by insiders.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $26.33 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. Centessa Pharmaceuticals PLC Sponsored ADR has a fifty-two week low of $9.60 and a fifty-two week high of $30.58. The company has a 50 day simple moving average of $24.69 and a two-hundred day simple moving average of $24.24. The company has a market capitalization of $3.85 billion, a PE ratio of -14.39 and a beta of 1.55.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.